ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

WAYNE, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in June.

  • On Wednesday June 4, 2025, at 10:30 AM EDT, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during Jefferies Global Healthcare Conference in New York, NY.



  • On Wednesday June 11, 2025, at 1:20 PM EDT, Dr. Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the 46th Annual Goldman Sachs Global Healthcare Conference in Miami, FL.

A live and archived webcast of both events will be accessible on the of . The webcasts will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit  and follow Aclaris on (formerly Twitter) at @AclarisTx and on .

Aclaris Therapeutics Contact:

Will Roberts

Senior Vice President

Corporate Communications and Investor Relations

(484) 329-2125





EN
28/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aclaris Therapeutics Inc.

 PRESS RELEASE

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammatio...

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference WAYNE, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provide a corporate presentation during the H.C. Wainwright Inflammation & Immunology Virtual Conference. The presentation will take place on Monday, June 30, 2025 at 11:30 AM EDT. A live and archived webcast of the presentation will be accessible ...

 PRESS RELEASE

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispe...

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052 - Potential Best-In-Class Bispecific Antibody ATI-052 Targets Both Thymic Stromal Lymphopoietin (TSLP) and Interleukin-4 Receptor (IL-4R) - WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiated a placebo-controlled Phase 1a/1b program for ATI-052, the Company’s potential best-in-class investigational bi...

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Dylan Shindler
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Yun Zhong

ResearchPool Subscriptions

Get the most out of your insights

Get in touch